Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Assets Average (2020 - 2025)

Historic Assets Average for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to $1.3 billion.

  • C4 Therapeutics' Assets Average fell 1483.16% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 1483.16%. This contributed to the annual value of $363.0 million for FY2024, which is 1006.3% down from last year.
  • C4 Therapeutics' Assets Average amounted to $1.3 billion in Q3 2025, which was down 1483.16% from $1.4 billion recorded in Q2 2025.
  • C4 Therapeutics' Assets Average's 5-year high stood at $2.0 billion during Q2 2022, with a 5-year trough of $816.3 million in Q1 2021.
  • In the last 5 years, C4 Therapeutics' Assets Average had a median value of $1.5 billion in 2024 and averaged $1.6 billion.
  • Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 61774.76% in 2021, then tumbled by 2221.13% in 2023.
  • Over the past 5 years, C4 Therapeutics' Assets Average (Quarter) stood at $1.9 billion in 2021, then increased by 3.99% to $1.9 billion in 2022, then dropped by 22.21% to $1.5 billion in 2023, then rose by 0.72% to $1.5 billion in 2024, then decreased by 15.29% to $1.3 billion in 2025.
  • Its Assets Average stands at $1.3 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.